Toxicités immunologiques induites par les inhibiteurs de checkpoint en 2019 : mise au point
- 24 October 2019
- journal article
- review article
- Published by Elsevier BV in La Revue de Médecine Interne
- Vol. 41 (1), 37-45
- https://doi.org/10.1016/j.revmed.2019.09.005
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- Acute interstitial nephritis related to immune checkpoint inhibitorsBritish Journal of Cancer, 2016
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialThe Lancet Oncology, 2016
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationNature Reviews Clinical Oncology, 2016
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitisNature Communications, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterJournal of Clinical Oncology, 2015
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2015
- Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsNature Reviews Cancer, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010